$1.71 Billion is the total value of Cormorant Asset Management, LP's 49 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 81.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | ENLIVEN THERAPEUTICS INC | $16,620,286 | -57.9% | 1,216,712 | -37.2% | 0.97% | -56.2% | |
| ZNTL | Sell | ZENTALIS PHARMACEUTICALS INC | $14,042,000 | -54.5% | 700,000 | -36.1% | 0.82% | -52.7% |
| AXNX | Sell | AXONICS INC | $14,030,000 | -13.7% | 250,000 | -22.4% | 0.82% | -10.2% |
| RNA | Sell | AVIDITY BIOSCIENCES INC | $11,242,294 | -61.2% | 1,762,115 | -32.5% | 0.66% | -59.6% |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $9,220,500 | -46.6% | 450,000 | -48.2% | 0.54% | -44.4% |
| BCEL | Exit | ATRECA INC | $0 | – | -319,057 | -100.0% | -0.02% | – |
| HARP | Exit | HARPOON THERAPEUTICS INC | $0 | – | -540,600 | -100.0% | -0.02% | – |
| GRPH | Exit | GRAPHITE BIO INC | $0 | – | -199,547 | -100.0% | -0.03% | – |
| GLTO | Exit | GALECTO INC | $0 | – | -1,020,238 | -100.0% | -0.14% | – |
| Exit | GREENLIGHT BIOSCIENCS HLDS P | $0 | – | -9,188,659 | -100.0% | -0.15% | – | |
| OCUL | Exit | OCULAR THERAPEUTIX INC | $0 | – | -645,000 | -100.0% | -0.19% | – |
| Exit | LEAP THERAPEUTICS INC | $0 | – | -1,073,046 | -100.0% | -0.19% | – | |
| APLS | Exit | APELLIS PHARMACEUTICALS INCcall | $0 | – | -39,000 | -100.0% | -0.20% | – |
| AKRO | Exit | AKERO THERAPEUTICS INC | $0 | – | -115,000 | -100.0% | -0.30% | – |
| AVIR | Exit | ATEA PHARMACEUTICALS INC | $0 | – | -1,547,181 | -100.0% | -0.32% | – |
| ARQT | Exit | ARCUTIS BIOTHERAPEUTICS INC | $0 | – | -800,000 | -100.0% | -0.43% | – |
| Exit | ASTRIA THERAPEUTICS INC | $0 | – | -1,000,000 | -100.0% | -0.47% | – | |
| MORF | Exit | MORPHIC HLDG INC | $0 | – | -150,000 | -100.0% | -0.48% | – |
| Exit | LIANBIOsponsored ads | $0 | – | -4,250,000 | -100.0% | -0.54% | – | |
| ISEE | Exit | IVERIC BIO INCcall | $0 | – | -300,000 | -100.0% | -0.66% | – |
| BBIO | Exit | BRIDGEBIO PHARMA INCput | $0 | – | -810,800 | -100.0% | -0.78% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -130,000 | -100.0% | -0.83% | – |
| VRDN | Exit | VIRIDIAN THERAPEUTICS INC | $0 | – | -850,000 | -100.0% | -1.13% | – |
| AXSM | Exit | AXSOME THERAPEUTICS INC | $0 | – | -340,000 | -100.0% | -1.37% | – |
| ETNB | Exit | 89BIO INC | $0 | – | -1,350,000 | -100.0% | -1.43% | – |
| DSGN | Exit | DESIGN THERAPEUTICS INC | $0 | – | -5,150,000 | -100.0% | -1.82% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -1,500,000 | -100.0% | -2.32% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.